- Home
- CNF vs QNCX Comparison
CNF vs QNCX Comparison
Compare CNF & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNF
- QNCX
- Stock Information
- Founded
- CNF 1999
- QNCX 2012
- Country
- CNF China
- QNCX United States
- Employees
- CNF N/A
- QNCX N/A
- Industry
- CNF Finance: Consumer Services
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNF Finance
- QNCX Health Care
- Exchange
- CNF Nasdaq
- QNCX Nasdaq
- Market Cap
- CNF 36.9M
- QNCX 43.2M
- IPO Year
- CNF 2018
- QNCX 2019
- Fundamental
- Price
- CNF $0.43
- QNCX $1.05
- Analyst Decision
- CNF
- QNCX Strong Buy
- Analyst Count
- CNF 0
- QNCX 5
- Target Price
- CNF N/A
- QNCX $8.00
- AVG Volume (30 Days)
- CNF 125.0K
- QNCX 611.7K
- Earning Date
- CNF 04-30-2025
- QNCX 05-13-2025
- Dividend Yield
- CNF N/A
- QNCX N/A
- EPS Growth
- CNF N/A
- QNCX N/A
- EPS
- CNF 0.08
- QNCX N/A
- Revenue
- CNF $85,661,735.00
- QNCX N/A
- Revenue This Year
- CNF $252.34
- QNCX N/A
- Revenue Next Year
- CNF N/A
- QNCX N/A
- P/E Ratio
- CNF $5.32
- QNCX N/A
- Revenue Growth
- CNF N/A
- QNCX N/A
- 52 Week Low
- CNF $0.37
- QNCX $0.51
- 52 Week High
- CNF $2.84
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- CNF 21.74
- QNCX 50.67
- Support Level
- CNF $0.65
- QNCX $1.01
- Resistance Level
- CNF $0.75
- QNCX $1.06
- Average True Range (ATR)
- CNF 0.06
- QNCX 0.11
- MACD
- CNF -0.03
- QNCX 0.02
- Stochastic Oscillator
- CNF 7.89
- QNCX 79.40
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.